논문 상세보기

대한소화기기능성질환·운동학회> Gut and Liver> Is the Risk for Venous Thromboembolism in East Asian Patients with Inflammatory Bowel Disease Comparable to That in Western Patients?

KCI등재

Is the Risk for Venous Thromboembolism in East Asian Patients with Inflammatory Bowel Disease Comparable to That in Western Patients?

Sung Wook Hwang
  • : 대한소화기기능성질환·운동학회
  • : Gut and Liver 16권4호
  • : 연속간행물
  • : 2022년 07월
  • : 495-496(2pages)
Gut and Liver

DOI


목차


					

키워드 보기


초록 보기


UCI(KEPA)

간행물정보

  • : 의약학분야  > 내과학
  • : KCI등재
  • :
  • : 격월
  • : 1976-2283
  • : 2005-1212
  • : 학술지
  • : 연속간행물
  • : 2007-2022
  • : 1487


저작권 안내

한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.

이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.

16권4호(2022년 07월) 수록논문
최근 권호 논문
| | | |

KCI등재

1Role of Tegoprazan in Helicobacter pylori Eradication Therapy

저자 : Jin Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 493-494 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

2Is the Risk for Venous Thromboembolism in East Asian Patients with Inflammatory Bowel Disease Comparable to That in Western Patients?

저자 : Sung Wook Hwang

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 495-496 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

3Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions

저자 : Jung Il Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 497-498 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

4Revolution of Novel Direct Peroral Cholangioscopy: Another Step Beyond Limitations

저자 : Tanyaporn Chantarojanasiri

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 499-500 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

5Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease

저자 : Eun Ae Kang , Jae Hee Cheon

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 501-502 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

6Management of Helicobacter pylori Infection: A Comparison between Korea and the United States

저자 : Sung Eun Kim , Joo Ha Hwang

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 503-514 (12 pages)

다운로드

(기관인증 필요)

초록보기

Helicobacter pylori has been well known to cause gastritis, peptic ulcers, mucosa-associated lymphoid tissue, and gastric cancer. The importance of H. pylori eradication has been emphasized; however, the management of H. pylori infection is difficult in clinical practice. In both Eastern and Western countries, there has been a constant interest in confirming individuals who should be tested and treated for H. pylori infection and developing methods to diagnose H. pylori infection. Many studies have been implemented to successfully eradicate H. pylori, and various combinations of eradication regimens for H. pylori infection have been suggested worldwide. Based on the findings of previous studies, a few countries have published their own guidelines that are appropriate for their country; however, these country-specific guidelines may differ depending on the circumstances in each country. Evidence-based guidelines and clinical practice updates for the treatment of H. pylori infection have been published in Korea and the United States in 2021. This review will summarize the similarities and differences in the management of H. pylori infection in Korea and the United States, focusing on indications, diagnosis, and treatments based on recent guidelines and recommendations in both countries. (Gut Liver 2022;16:503-514)

KCI등재

7Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

저자 : Jia-feng Wu

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 515-524 (10 pages)

다운로드

(기관인증 필요)

초록보기

During the past decade, we have entered an era of biologics for the treatment of Crohn's disease and ulcerative colitis. The therapeutic goal of inflammatory bowel disease (IBD) management has evolved from symptom control and clinical remission to mucosal healing or even deep remission. Histological remission for ulcerative colitis and transmural healing of Crohn's disease are potential future goals. With the adoption of the treat-to-target concept, and given the need for tight control of IBD activity, therapeutic drug monitoring (TDM) is an important element of precision medicine. TDM involves the measurement of serum biologics and anti-drug antibodies levels, to confirm whether the right drug with the right dosage was prescribed to reach the right serum levels. TDM may help clinicians adjust biologics based on objective biomarkers instead of using empirical dosage escalation or making symptom-based therapeutic adjustments. Wellestablished reactive TDM algorithms have been proposed, and emerging evidence supports the clinical application of a proactive TDM strategy to enhance the duration of effective biologics and improve clinical outcomes. Recently, the proactive TDM strategy was shown to avoid the secondary loss of response to biologics, and improve long-term clinical outcomes in IBD patients. This review summarizes data from trials, and practice guidelines, on the clinical application of proactive and reactive TDM strategies for the daily care of biologic-treated IBD patients. (Gut Liver 2022;16:515-524)

KCI등재

8Endoscopic Reintervention for Recurrence of Malignant Biliary Obstruction: Developing the Best Strategy

저자 : Mamoru Takenaka , Masatoshi Kudo

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 525-534 (10 pages)

다운로드

(기관인증 필요)

초록보기

Drainage therapy for malignant biliary obstruction (MBO) includes trans-papillary endoscopic retrograde biliary drainage (ERBD), percutaneous transhepatic biliary drainage (PTBD), and transgastrointestinal endoscopic ultrasound-guided biliary drainage (EUS-BD). With the development of chemotherapy, many MBO cases end up needing endoscopic reintervention (E-RI) for recurrent biliary obstruction. To achieve a successful E-RI, it is necessary to understand the various findings regarding E-RI in MBO cases reported to date. Therefore, in this review, we focus on E-RI for ERBD of distal MBO, ERBD of hilar MBO, and EUS-BD. To plan an appropriate E-RI strategy for biliary stent occlusion for MBO, the following must be considered on a case-by-case basis: the urgency of the drainage, the cause of the occlusion, the original route of drainage (PTBD/ERBD/EUS-BD), the initial stent used (plastic stent or self-expandable metallic stent), and in the case of self-expandable metallic stents, the type used (fully covered or uncovered). Regardless of the original method of stent placement, if the inflammation caused by obstructive cholangitis is severe and/or the patient is in shock, PTBD should be considered as the first choice. Finally, it is important to keep in mind that in many cases, performing E-RI will be difficult. (Gut Liver 2022;16:525-534)

KCI등재

9Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial

저자 : Yoon Jin Choi , Yong Chan Lee , Jung Mogg Kim , Jin Il Kim , Jeong Seop Moon , Yun Jeong Lim , Gwang Ho Baik , Byoung Kwan Son , Hang Lak Lee , Kyoung Oh Kim , Nayoung Kim , Kwang Hyun Ko , Hye-kyung Jung

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 535-546 (12 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.
Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.
Results: In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.
Conclusions: TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier NCT03317223). (Gut Liver 2022;16:535-546)

KCI등재

10Long-term Outcomes of Additional Endoscopic Treatments for Patients with Positive Lateral Margins after Endoscopic Submucosal Dissection for Early Gastric Cancer

저자 : Tae-se Kim , Byung-hoon Min , Yang Won Min , Hyuk Lee , Poong-lyul Rhee , Jae J. Kim , Jun Haeng Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 547-554 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: It is uncertain whether additional endoscopic treatment may be chosen over surgery in patients with positive lateral margins (pLMs) as the only non-curative factor after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). We aimed to compare the long-term outcomes of additional endoscopic treatments in such patients with those of surgery and elucidate the clinicopathological factors that could influence the treatment selection.
Methods: A total of 99 patients with 101 EGC lesions undergoing additional treatment after noncurative ESD with pLMs as the only non-curative factor were analyzed. Among them, 25 (27 lesions) underwent ESD, 29 (29 lesions) underwent argon plasma coagulation (APC), and 45 (45 lesions) underwent surgery. Clinicopathological characteristics and long-term outcomes were compared.
Results: Residual tumor was found in 73.6% of cases. The presence of multiple pLMs was associated with higher risk of residual tumor (p=0.046). During a median follow-up of 58.9 months, recurrent or residual lesions after additional ESD and APC were found in 4% (1/25) and 6.8% (2/29) of patients, respectively. However, all were completely cured with surgery or repeated ESD. There were no extragastric recurrences after additional endoscopic treatment. Lymph node metastasis was identified after additional surgery in one (2.2%) patient with an EGC showing histological heterogeneity.
Conclusions: Given the favorable long-term outcomes, additional ESD or APC may be an acceptable choice for patients with pLMs as the only non-curative factor after ESD for EGC. However, clincopathological characteristics such as multiple pLMs and histological heterogeneity should be considered in the treatment selection. (Gut Liver 2022;16:547-554)

12
권호별 보기
같은 권호 다른 논문
| | | | 다운로드

KCI등재

1Role of Tegoprazan in Helicobacter pylori Eradication Therapy

저자 : Jin Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 493-494 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

3Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions

저자 : Jung Il Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 497-498 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

4Revolution of Novel Direct Peroral Cholangioscopy: Another Step Beyond Limitations

저자 : Tanyaporn Chantarojanasiri

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 499-500 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

5Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease

저자 : Eun Ae Kang , Jae Hee Cheon

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 501-502 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

6Management of Helicobacter pylori Infection: A Comparison between Korea and the United States

저자 : Sung Eun Kim , Joo Ha Hwang

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 503-514 (12 pages)

다운로드

(기관인증 필요)

초록보기

Helicobacter pylori has been well known to cause gastritis, peptic ulcers, mucosa-associated lymphoid tissue, and gastric cancer. The importance of H. pylori eradication has been emphasized; however, the management of H. pylori infection is difficult in clinical practice. In both Eastern and Western countries, there has been a constant interest in confirming individuals who should be tested and treated for H. pylori infection and developing methods to diagnose H. pylori infection. Many studies have been implemented to successfully eradicate H. pylori, and various combinations of eradication regimens for H. pylori infection have been suggested worldwide. Based on the findings of previous studies, a few countries have published their own guidelines that are appropriate for their country; however, these country-specific guidelines may differ depending on the circumstances in each country. Evidence-based guidelines and clinical practice updates for the treatment of H. pylori infection have been published in Korea and the United States in 2021. This review will summarize the similarities and differences in the management of H. pylori infection in Korea and the United States, focusing on indications, diagnosis, and treatments based on recent guidelines and recommendations in both countries. (Gut Liver 2022;16:503-514)

KCI등재

7Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

저자 : Jia-feng Wu

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 515-524 (10 pages)

다운로드

(기관인증 필요)

초록보기

During the past decade, we have entered an era of biologics for the treatment of Crohn's disease and ulcerative colitis. The therapeutic goal of inflammatory bowel disease (IBD) management has evolved from symptom control and clinical remission to mucosal healing or even deep remission. Histological remission for ulcerative colitis and transmural healing of Crohn's disease are potential future goals. With the adoption of the treat-to-target concept, and given the need for tight control of IBD activity, therapeutic drug monitoring (TDM) is an important element of precision medicine. TDM involves the measurement of serum biologics and anti-drug antibodies levels, to confirm whether the right drug with the right dosage was prescribed to reach the right serum levels. TDM may help clinicians adjust biologics based on objective biomarkers instead of using empirical dosage escalation or making symptom-based therapeutic adjustments. Wellestablished reactive TDM algorithms have been proposed, and emerging evidence supports the clinical application of a proactive TDM strategy to enhance the duration of effective biologics and improve clinical outcomes. Recently, the proactive TDM strategy was shown to avoid the secondary loss of response to biologics, and improve long-term clinical outcomes in IBD patients. This review summarizes data from trials, and practice guidelines, on the clinical application of proactive and reactive TDM strategies for the daily care of biologic-treated IBD patients. (Gut Liver 2022;16:515-524)

KCI등재

8Endoscopic Reintervention for Recurrence of Malignant Biliary Obstruction: Developing the Best Strategy

저자 : Mamoru Takenaka , Masatoshi Kudo

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 525-534 (10 pages)

다운로드

(기관인증 필요)

초록보기

Drainage therapy for malignant biliary obstruction (MBO) includes trans-papillary endoscopic retrograde biliary drainage (ERBD), percutaneous transhepatic biliary drainage (PTBD), and transgastrointestinal endoscopic ultrasound-guided biliary drainage (EUS-BD). With the development of chemotherapy, many MBO cases end up needing endoscopic reintervention (E-RI) for recurrent biliary obstruction. To achieve a successful E-RI, it is necessary to understand the various findings regarding E-RI in MBO cases reported to date. Therefore, in this review, we focus on E-RI for ERBD of distal MBO, ERBD of hilar MBO, and EUS-BD. To plan an appropriate E-RI strategy for biliary stent occlusion for MBO, the following must be considered on a case-by-case basis: the urgency of the drainage, the cause of the occlusion, the original route of drainage (PTBD/ERBD/EUS-BD), the initial stent used (plastic stent or self-expandable metallic stent), and in the case of self-expandable metallic stents, the type used (fully covered or uncovered). Regardless of the original method of stent placement, if the inflammation caused by obstructive cholangitis is severe and/or the patient is in shock, PTBD should be considered as the first choice. Finally, it is important to keep in mind that in many cases, performing E-RI will be difficult. (Gut Liver 2022;16:525-534)

KCI등재

9Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial

저자 : Yoon Jin Choi , Yong Chan Lee , Jung Mogg Kim , Jin Il Kim , Jeong Seop Moon , Yun Jeong Lim , Gwang Ho Baik , Byoung Kwan Son , Hang Lak Lee , Kyoung Oh Kim , Nayoung Kim , Kwang Hyun Ko , Hye-kyung Jung

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 535-546 (12 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.
Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.
Results: In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.
Conclusions: TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier NCT03317223). (Gut Liver 2022;16:535-546)

KCI등재

10Long-term Outcomes of Additional Endoscopic Treatments for Patients with Positive Lateral Margins after Endoscopic Submucosal Dissection for Early Gastric Cancer

저자 : Tae-se Kim , Byung-hoon Min , Yang Won Min , Hyuk Lee , Poong-lyul Rhee , Jae J. Kim , Jun Haeng Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 547-554 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: It is uncertain whether additional endoscopic treatment may be chosen over surgery in patients with positive lateral margins (pLMs) as the only non-curative factor after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). We aimed to compare the long-term outcomes of additional endoscopic treatments in such patients with those of surgery and elucidate the clinicopathological factors that could influence the treatment selection.
Methods: A total of 99 patients with 101 EGC lesions undergoing additional treatment after noncurative ESD with pLMs as the only non-curative factor were analyzed. Among them, 25 (27 lesions) underwent ESD, 29 (29 lesions) underwent argon plasma coagulation (APC), and 45 (45 lesions) underwent surgery. Clinicopathological characteristics and long-term outcomes were compared.
Results: Residual tumor was found in 73.6% of cases. The presence of multiple pLMs was associated with higher risk of residual tumor (p=0.046). During a median follow-up of 58.9 months, recurrent or residual lesions after additional ESD and APC were found in 4% (1/25) and 6.8% (2/29) of patients, respectively. However, all were completely cured with surgery or repeated ESD. There were no extragastric recurrences after additional endoscopic treatment. Lymph node metastasis was identified after additional surgery in one (2.2%) patient with an EGC showing histological heterogeneity.
Conclusions: Given the favorable long-term outcomes, additional ESD or APC may be an acceptable choice for patients with pLMs as the only non-curative factor after ESD for EGC. However, clincopathological characteristics such as multiple pLMs and histological heterogeneity should be considered in the treatment selection. (Gut Liver 2022;16:547-554)

12
발행기관 최신논문
자료제공: 네이버학술정보
발행기관 최신논문
자료제공: 네이버학술정보

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기